Peer-Reviewed Journal Details
Mandatory Fields
Norris, PT;Wilson, SE;Green, JA;Gu, J;Goddard, S;Deadman, LR;Dai, J;Fastier, K;Kothapally, C;Shi, W;Whyte, A;Aslam, H;Desai, R;Wood, N;Sibley, CG
2018
February
Research In Social & Administrative Pharmacy
Knowledge and attitudes to prescription charges in New Zealand and England
Published
1 ()
Optional Fields
MEDICATION USE HEALTH-STATUS COST MEDICINES ACCESS VIEWS SERVICES BEHAVIOR PEOPLE ADULTS
14
180
186
Background: Prescription charge regimes vary between countries but there is little research on how much people know about these or support values underlying them. Objective: To explore, in New Zealand (NZ) and England, the public's knowledge of, and attitudes to, charges and whether knowledge and attitudes varied by demographic characteristics or by values about entitlement to public goods. Method: A questionnaire was developed and administered to people over 18 recruited in public places in NZ and England. Results: 451 people in NZ and 300 people in England participated. Less than half in each country knew the current prescription charge. In each country 62% of people were unaware of arrangements to protect people from excessive annual charges. Support for free or lower cost medicines for children, people over 65, people on low incomes, people on benefits, and people with chronic health problems was higher in England than in NZ. Support varied by participants' demographic characteristics and, in the case of people on low incomes and people on benefits, by values about universal entitlements. Discussion: Gaps in knowledge, particularly about mechanisms to protect people from high costs, are concerning and may lead to people paying excessive charges. There was consensus about the elderly, children and the chronically ill being "deserving" of lower prescription charges, but people who did not believe in universal access to public goods appeared to see people on low incomes or benefits as less "deserving". In general, public views resembled those underlying the prescription charge regime in their country. (C) 2017 Elsevier Inc. All rights reserved.
NEW YORK
1551-7411
10.1016/j.sapharm.2017.02.016
Grant Details